Table 1. Clinico-pathological features.

Characteristics	All n = 90 n (%)	nt-FL n = 49 n (%)	s-FL n = 41 n (%)	P-value
Sex				NS
Male	46 (51)	21 (43)	25 (61)
Female	44 (49)	28 (57)	16 (39)
Age at FL diagnosis				NS
Median	57	57	57
Range	25–83	35–83	25–78
Ann Arbor stage				<0.001
I-II	29 (32)	24(49)	5 (12)
III-IV	59 (66)	24 (49)	35 (85)
Unknown	2 (2)	1 (2)	1 (3)
FLIPI				0.001
Low	33 (37)	25 (51)	8 (20)
Intermediate	28 (31)	16 (33)	12 (29)
High	25 (28)	6 (12)	19 (46)
Unknown	4 (4)	2 (4)	2 (5)
LDH-elevation				0.038
Yes	15 (17)	4 (8)	11 (27)
No	71 (79)	43 (88)	28 (68)
Unknown	4 (4)	2 (4)	2 (5)
B-symptoms				NS
Yes	22 (24)	9 (18)	13 (32)
No	63 (70)	38 (78)	25 (61)
Unknown	5 (6)	2 (4)	3 (7)
Performance score				NS
< 2	85 (95)	46 (94)	39 (95)
≥ 2	2 (2)	2 (4)	0 (0)
Unknown	3 (3)	1 (2)	2 (5)
Bone marrow				0.035
Involvement	26 (29)	9 (18)	17 (41)
No	50 (56)	33 (67)	17 (41)
Unknown	14 (15)	7 (14)	7 (18)
Anemia				NS
Yes	6 (7)	1 (2)	5 (12)
No	81 (90)	47 (96)	34 (83)
Unknown	3 (3)	1 (2)	2 (5)
FL histology				NS
FL NOS	1 (1)	0 (0)	1 (2)
FL grade 1–2	74 (82)	39 (80)	35 (86)
FL grade 3A	15 (17)	10 (20)	5 (12)
Initial treatment				NA
Alkylator-based	24 (27)	16 (33)	8 (20)
Antracyclin-based	8 (9)	2 (4)	6 (15)
Chlorambucil	20 (22)	11 (22)	9 (22)
Rituximab only	9 (10)	2 (4)	7 (17)
Radiation only	7 (8)	5 (10)	2 (5)
Watch and wait	20 (22)	13 (27)	7 (17)
Other	2 (2)	0 (0)	2 (5)
R-Chemo	29 (32)	11 (22)	18 (44)
Aldolase A expression				<0.001
Low	67 (74)	44 (90)	23 (56)
High	23 (26)	5 (10)	18 (44)
GAPDH expression				<0.001
Low	66 (75)	44 (90)	22 (56)
High	22 (25)	5 (10)	17 (44)